Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer

Phase 2

Conditions: Triple-negative Breast Cancer

Interventions: Drug: Chidamide combined with Cisplatin

First Posted Date: 2019-12-10

Last Posted Date: 2022-04-20

Lead Sponsor: Fudan University

Target Recruit Count: 55

Registration Number: NCT04192903

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer

Phase 3

Conditions: Breast Cancer

Interventions: Drug: Epirubicin
Drug: Paclitaxel
Drug: Cyclophosphamide
Drug: Carboplatin
Drug: Docetaxel
Drug: Trastuzumab
Drug: Pertuzumab

First Posted Date: 2019-12-10

Last Posted Date: 2020-03-09

Lead Sponsor: Fudan University

Target Recruit Count: 1560

Registration Number: NCT04193059

Locations: 🇨🇳
Cancer Hospital Affiliated to Fudan University, Shanghai, Shanghai, China

HRCT in Prediction of Tumor Invasion in GGO Lung Adenocarcinoma (ECTOP-1008)

Completed

Conditions: Adenocarcinoma of Lung

First Posted Date: 2019-11-18

Last Posted Date: 2023-07-21

Lead Sponsor: Fudan University

Target Recruit Count: 620

Registration Number: NCT04165759

Locations: 🇨🇳
Fudan University Cancer Center, Shanghai, Shanghai, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients

Phase 2

Completed

Conditions: Double Expressor Lymphoma

Interventions: Drug: Lenalidomide combined with R-CHOP

First Posted Date: 2019-11-15

Last Posted Date: 2024-05-13

Lead Sponsor: Fudan University

Target Recruit Count: 67

Registration Number: NCT04164368

Locations: 🇨🇳
270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, China

Acute Health Effects of Traffic-Related Air Pollution Exposure

Not Applicable

Conditions: Cardiovascular System
Respiratory System

Interventions: Behavioral: Walking along a busy road
Behavioral: Walking in a traffic-free park

First Posted Date: 2019-11-06

Last Posted Date: 2022-03-16

Lead Sponsor: Fudan University

Target Recruit Count: 69

Registration Number: NCT04153539

Locations: 🇨🇳
Department of Environmental Health, School of Public Health, Fudan University, Shanghai, Shanghai, China

Clinical Study on the Improvement of Diabetic Neuropathic Pain by Liraglutide

Not Applicable

Conditions: Diabetic Neuropathic Pain

Interventions: Drug: insulin
Drug: Liraglutide

First Posted Date: 2019-10-24

Last Posted Date: 2019-10-25

Lead Sponsor: Fudan University

Target Recruit Count: 60

Registration Number: NCT04137328

Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC

Phase 2

Conditions: NSCLC Stage IV

Interventions: Drug: Pemetrexed
Drug: Carboplatin
Drug: Anlotinib

First Posted Date: 2019-10-23

Last Posted Date: 2019-10-23

Lead Sponsor: Fudan University

Target Recruit Count: 105

Registration Number: NCT04136535

Locations: 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China

A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)

Phase 2

Conditions: Triple-Negative Breast Cancer

Interventions: Drug: camrelizumab in combination with nab-paclitaxel and famitinib

First Posted Date: 2019-10-17

Last Posted Date: 2022-01-11

Lead Sponsor: Fudan University

Target Recruit Count: 46

Registration Number: NCT04129996

Locations: 🇨🇳
Zhi-Ming Shao, Shanghai, China

Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)

Phase 3

Completed

Conditions: Primary Breast Cancer

Interventions: Drug: Docetaxel
Drug: Paclitaxel
Drug: Cyclophosphamide
Drug: Epirubicin
Drug: 5-fluorouracil

First Posted Date: 2019-10-15

Last Posted Date: 2020-02-26

Lead Sponsor: Fudan University

Target Recruit Count: 2079

Registration Number: NCT04127019

SIB in Upper Thoracic Esophageal Squamous Cell Carcinoma

Phase 2

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Radiation: Simultaneous integrated boost intensity-modulated chemoradiotherapy

First Posted Date: 2019-10-04

Last Posted Date: 2019-10-04

Lead Sponsor: Fudan University

Target Recruit Count: 65

Registration Number: NCT04115618

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy